Skip to main content

Table 5 Treatments five to one year before or one year after hospitalisation with a diagnosis of IBS in France in 2015 according to ATC code and the number of reimbursements of some drugs

From: Healthcare use by 30,000 patients with irritable bowel syndrome (IBS) in France: a 5-year retrospective and one-year prospective national observational study

  Before hospitalisation After hospitalisation
Year −5 −4 −3 −2 −1 year + 1 year
Age All All All All All* 18–39 40–59 60–74 75 + All* 18–39 40–59 60–74 75 +
Drugs (ATC code) % % % % % % % % % % % % % %
Drugs for functional GI disorders (A03)
 0 reimbursement 14.7 17.5 21.2 26.5 34.8 27.0 35.4 40.4 36.9 48.9 42.5 49.5 53.9 49.0
 1–2 24.0 26.4 29.0 32.4 35.4 39.5 36.8 31.6 29.1 33.1 37.7 33.7 29.3 28.8
 3 or more 61.3 56.1 49.8 41.1 29.7 33.5 27.8 28.0 34.1 18.0 19.8 16.8 16.8 22.2
Drugs for functional GI disorders (A03A)
 0 19.7 22.8 26.8 32.3 40.7 32.1 41.0 47.0 44.4 53.9 47.3 54.1 59.1 55.0
 1–2 29.2 31.0 32.8 34.8 36.0 42.8 37.0 30.8 28.5 32.3 38.2 32.9 27.7 27.3
 3 or more 51.1 46.2 40.5 32.9 23.2 25.1 22.0 22.2 27.1 13.8 14.5 13.0 13.1 17.7
Antispasmodics or anticholinergics in combination with other drugs (A03C-D-E)
 0 80.2 82.0 84.1 86.2 89.1 88.7 89.0 89.2 89.8 92.4 92.3 92.3 92.7 92.6
 1–2 15.3 14.2 12.9 11.5 9.5 10.4 9.8 8.9 7.8 6.8 7.3 7.1 6.3 5.9
 3 or more 4.6 3.8 3.1 2.2 1.4 0.9 1.2 1.8 2.4 0.7 0.4 0.6 0.9 1.6
Propulsives (A03F)
 0 54.9 61.0 67.2 74.7 82.8 76.9 84.3 85.7 82.4 89.8 86.7 90.8 91.2 89.1
 1–2 30.6 28.2 25.0 20.4 15.0 20.8 14.0 11.9 13.0 9.3 12.4 8.6 7.8 9.1
 3 or more 14.5 10.9 7.8 4.9 2.3 2.2 1.7 2.4 4.6 0.9 0.8 0.6 1.1 1.8
Laxatives (A06)
 0 4.8 5.2 5.8 6.7 7.8 9.4 5.5 6.4 19.4 11.3 12.4 8.8 9.8 24.7
 1–2 57.9 61.3 64.7 68.3 72.6 75.5 76.7 72.0 46.0 74.9 77.1 78.7 74.9 50.8
 3 or more 37.3 33.5 29.5 25.0 19.6 15.1 17.8 21.6 34.5 13.8 10.5 12.5 15.3 24.5
Laxatives (A06)a
 0 33.7 35.9 38.6 41.8 46.2 48.2 46.9 45.4 39.8 52.0 53.6 52.6 51.0 47.6
 1–2 38.2 38.7 39.2 39.6 39.9 42.5 41.2 38.8 30.4 38.9 40.3 39.5 38.5 33.0
 3 or more 28.1 25.3 22.1 18.5 13.9 9.4 11.9 15.9 29.8 9.1 6.1 7.9 10.5 19.4
Softeners, emollients (A06AA)
 0 92.7 93.4 94.2 95.1 96.2 96.8 96.6 96.1 93.2 97.3 97.9 97.6 97.3 94.7
 1–2 5.7 5.2 4.6 3.9 3.1 2.9 2.8 2.9 5.0 2.2 2.0 2.0 2.2 4.2
 3 or more 1.6 1.4 1.2 1.0 0.7 0.2 0.6 0.9 1.8 0.4 0.2 0.3 0.6 1.2
Contact laxatives (A06AB)
 0 72.9 73.4 74.1 74.7 75.0 73.5 73.7 75.1 85.4 75.9 74.3 74.7 76.0 86.0
 1–2 26.9 26.4 25.8 25.3 24.9 26.4 26.2 24.9 14.5 24.1 25.6 25.3 24.0 13.9
 3 or more 0.2 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0
Bulk-forming laxatives (A06AC)
 0 85.0 86.4 88.1 89.6 91.7 92.8 91.9 91.4 88.2 93.6 94.5 93.7 93.3 91.8
 1–2 10.7 9.9 8.8 7.9 6.7 6.5 6.9 6.1 8.0 5.5 5.1 5.7 5.3 6.3
 3 or more 4.3 3.7 3.1 2.4 1.7 0.7 1.2 2.6 3.8 0.9 0.4 0.7 1.4 1.9
Osmotically acting laxatives (A06AD)
 0 17.1 18.7 20.2 22.0 24.4 28.0 22.4 22.6 29.8 28.5 31.5 26.4 26.6 35.9
 1–2 58.3 60.0 61.4 62.9 64.5 65.0 68.0 64.8 45.8 64.5 64.0 67.8 65.1 48.3
 3 or more 24.6 21.3 18.4 15.1 11.0 7.0 9.5 12.6 24.4 7.0 4.5 5.9 8.3 15.8
Enemas (A06AG)
 0 84.0 85.4 86.9 88.5 90.4 89.5 91.4 91.0 86.5 92.2 91.4 92.9 92.8 89.4
 1–2 14.4 13.3 12.2 10.8 9.2 10.3 8.3 8.5 12.5 7.6 8.4 7.0 7.0 10.1
 3 or more 1.6 1.3 1.0 0.7 0.4 0.3 0.2 0.5 1.0 0.2 0.2 0.1 0.2 0.5
Antidiarrheals, intestinal antiinflammatory/antiinfective agents (A07)
 0 51.2 55.7 60.6 67.0 75.0 67.6 77.7 78.5 71.7 82.3 77.1 84.4 85.0 77.7
 1–2 31.6 30.0 27.8 24.5 19.6 27.4 17.6 16.0 19.1 14.7 20.2 12.9 11.9 16.2
 3 or more 17.1 14.3 11.6 8.4 5.4 5.0 4.7 5.5 9.2 3.1 2.6 2.7 3.1 6.1
Antipropulsives (A07D)
 0 68.4 72.0 75.6 80.1 85.2 82.7 86.6 86.4 80.9 89.7 88.2 90.8 90.7 85.2
 1–2 23.1 21.0 18.6 15.6 12.1 15.4 10.9 10.5 14.1 8.8 10.9 7.8 7.7 11.7
 3 or more 8.5 7.0 5.7 4.2 2.7 1.9 2.5 3.1 5.0 1.5 1.0 1.4 1.6 3.1
Other antidiarrheals (A07X)
 0 69.7 72.9 76.5 81.0 86.3 80.6 88.0 89.4 84.7 90.7 86.9 91.8 92.8 88.6
 1–2 24.6 22.4 20.0 16.8 12.5 18.3 11.0 9.5 13.3 8.8 12.5 7.7 6.6 10.3
 3 or more 5.7 4.6 3.4 2.2 1.1 1.2 1.0 1.1 2.0 0.6 0.5 0.5 0.6 1.1
Antidepressants
 0 reimbursement 63.9 66.9 70.2 73.8 78.7 86.1 77.6 76.2 71.2 83.1 89.7 82.3 80.6 76.1
 1–2 10.3 9.4 8.4 7.4 5.9 6.3 6.0 5.0 6.5 6.4 5.2 6.6 6.6 8.0
 3 or more 25.8 23.7 21.5 18.8 15.4 7.6 16.3 18.7 22.3 10.5 5.2 11.0 12.8 15.8
Neuroleptics
 0 92.8 93.6 94.3 95.3 96.4 97.3 96.1 96.5 95.3 97.2 98.0 96.9 97.2 96.2
 1–2 2.8 2.4 2.1 1.6 1.1 1.1 1.2 0.9 1.6 1.2 0.9 1.2 1.2 1.8
 3 or more 4.4 4.0 3.6 3.1 2.5 1.7 2.7 2.6 3.2 1.6 1.1 1.9 1.6 2.0
Anxiolytics
 0 42.1 46.2 51.2 57.6 67.5 74.5 66.8 65.4 58.1 76.6 83.1 76.5 74.0 66.7
 1–2 23.8 23.2 22.1 20.2 16.0 17.7 17.3 13.9 12.2 13.3 12.4 13.8 13.1 14.0
 3 or more 34.1 30.6 26.7 22.3 16.4 7.9 15.9 20.6 29.7 10.1 4.5 9.6 12.8 19.3
Hypnotics
 0 72.1 74.8 78.0 81.5 86.0 93.5 86.0 82.1 77.8 89.7 95.6 90.0 86.2 82.6
 1–2 12.2 11.1 9.6 8.1 6.0 4.1 6.8 6.5 5.7 5.4 2.8 5.5 7.0 7.3
 3 or more 15.7 14.1 12.4 10.4 8.0 2.4 7.3 11.4 16.4 4.9 1.6 4.4 6.7 10.1
  1. aexcluding drugs indicated for purge in a context of colonoscopy preparation
  2. *P < 0.0001 for distribution comparisons between “all −1 year” vs “all 1 year”